Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TG Therapeutics Inc (NASDAQ:TGTX)

11.40
Delayed Data
As of Mar 24
 +0.50 / +4.59%
Today’s Change
4.10
Today|||52-Week Range
15.05
+145.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$682.3M

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company. It focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
2 Gansevoort Street
New York New York 10014
P:(212) 554-4484
Investor Relations:
(212) 554-4351

Employees

Shareholders

Other institutional22.32%
Mutual fund holders18.40%
Individual stakeholders11.56%

Top Executives

Michael Sean WeissExecutive Chairman, President & CEO
Sean A. PowerCFO, Secretary, Treasurer & CAO
Robert NiecestroExecutive Vice President-Clinical & Regulatory
Hari MiskinVice President-Business Development
Jenna A. BoscoDirector-Investor Relations & Media Inquiries